Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;9(2):583-590.
doi: 10.21037/tau.2020.01.05.

A safety and efficacy analysis of direct-antiviral therapy in patients with chronic hepatitis C after renal transplantation

Guanghui Li  1 , Junjie Ma  1 , Lu Xu  1 , Jiali Fang  1 , Lei Zhang  1 , Jialin Wu  1 , Xingqiang Lai  1 , Luhao Liu  1 , Yunyi Xiong  1 , Wei Yin  1 , Tao Zhang  1 , Peng Zhang  1 , Li Li  1 , Rongxin Chen  1 , Jiao Wang  1 , Zheng Chen  1
Affiliations

A safety and efficacy analysis of direct-antiviral therapy in patients with chronic hepatitis C after renal transplantation

Guanghui Li et al. Transl Androl Urol. 2020 Apr.

Abstract

Background: To explore the safety and efficacy of direct antiviral therapy in patients with hepatitis C virus (HCV) infection after renal transplantation.

Methods: We retrospectively reviewed the medical information of 15 cases of HCV+ patients treated with direct antiviral therapy after renal transplantation in our center. The effectiveness of direct antiviral therapy was evaluated by analyzing the HCV-RNA levels of patients at 1, 4, 12, 24, and 48 weeks before and after antiviral therapy. In addition, parameters including the rejection rate, the blood concentration of anti-rejection drugs, liver function level [alanine aminotransferase (ALT), aspartate transaminase (AST)], estimated glomerular filtration rate (eGFR) and serum creatinine (CREA) levels were used to assess its safety.

Results: A total of 15 patients were enrolled in the study. All patients turned HCV-RNA negative after 12 weeks of direct-antiviral therapy; the serological test of all patients demonstrated an 100% response rate in rapid virological response (RVR) (15/15), 12-week sustained virological response (SVR12), and 24-week sustained virological response (SVR24). In addition, compared to pre-treatment, the liver function within 12, 24, and 48 weeks after treatment was significantly improved. Moreover, eGFR, CREA, and anti-rejection drug concentration remained stable while acute rejection reaction and other obvious side effects were not observed throughout the treatment period.

Conclusions: The direct antiviral therapy was well-tolerated and effective for patients with chronic hepatitis C after renal transplantation.

Keywords: Renal transplantation; chronic hepatitis C; direct antiviral drugs; virological response.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau.2020.01.05). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
HCV-RNA in 15 patients before and after DDA treatment. All patients received DAA treatment; HCV-RNA levels decreased to the normal range at about 1 week. HCV, hepatitis C virus; DAA, direct antiviral agent.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Solli P, Dolci G, Ranieri VM. The new frontier of hepatitis C virus (HCV)-mismatched heart and lung transplantation. Ann Transl Med 2019;7:S279. 10.21037/atm.2019.11.123 - DOI - PMC - PubMed
    1. Cacoub P, Gragnani L, Comarnond C, et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014;46:S165-73. 10.1016/j.dld.2014.10.005 - DOI - PubMed
    1. Shah HH, Patel C. Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis. Ren Fail 2013;35:1182-5. 10.3109/0886022X.2013.815568 - DOI - PubMed
    1. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008;(109):S1-99. - PubMed
    1. Ingsathit A, Kamanamool N, Thakkinstian A, et al. Survival advantage of kidney transplantation over dialysis in patients with hepatitis C: a systematic review and meta-analysis. Transplantation 2013;95:943-48. 10.1097/TP.0b013e3182848de2 - DOI - PubMed